|1.||Soriano, Vincent: 2 articles (03/2015 - 09/2008)|
|2.||De Clercq, Erik: 2 articles (11/2013 - 09/2008)|
|3.||Zhan, Peng: 2 articles (04/2013 - 01/2009)|
|4.||Ceccherini-Silberstein, Francesca: 2 articles (12/2012 - 11/2011)|
|5.||Dreyfus, David H: 2 articles (12/2011 - 11/2006)|
|6.||Hazuda, Daria J: 2 articles (09/2010 - 05/2006)|
|7.||Markowitz, Martin: 2 articles (09/2010 - 12/2007)|
|8.||Croxtall, Jamie D: 2 articles (05/2009 - 01/2008)|
|9.||Savarino, Andrea: 2 articles (01/2007 - 12/2006)|
|10.||Skalweit, Marion J: 1 article (09/2015)|
01/01/2008 - "Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection."
05/01/2006 - "It is only recently, however, that the efficacy of integrase inhibitors has been demonstrated in experimental animal model systems of retroviral infection, and in HIV-1 infected subjects. "
02/05/2010 - "Among the NRTI, NNRTI and integrase inhibitors used in this study, only AZT blocked XMRV infection and replication through inhibition of viral reverse transcription. "
03/01/2015 - "Integrase inhibitors are the latest drug family to be added to the therapeutic arsenal against human immunodeficiency virus infection. "
03/01/2015 - "Dolutegravir may be a good therapeutic option for patients with HIV-2 infection, including those that previously failed other integrase inhibitors."
|2.||HIV Infections (HIV Infection)
11/01/2008 - "The first generation of integrase inhibitors recently approved or currently in late-stage clinical trials shows great promise for the treatment of human immunodeficiency virus (HIV) infection, but virus is expected to develop resistance to these drugs. "
06/01/2015 - "Integrase inhibitors (INIs) are the latest class of antiretroviral drugs approved for the treatment of HIV infection and are becoming 'standard' drugs in the treatment of both naïve as well as heavily pretreated individuals with HIV. "
01/01/2014 - "Integrase inhibitors are a promising class of antiretroviral drugs to treat chronic human immunodeficiency virus (HIV) infection. "
12/01/2013 - "Rational design of LEDGINs as first allosteric integrase inhibitors for the treatment of HIV infection."
05/01/2013 - "Thus, entry and integrase inhibitors present a real added value in combined treatment against HIV infection. "
|3.||Human Influenza (Influenza)
11/15/2013 - "In this second part of "Dancing with antivirals as chemical formulae" I will focus on a number of chemical compounds that in the last few years have elicited more than common attraction from a commercial viewpoint: (i) favipiravir (T-705), as it is active against influenza, but also several other RNA viruses; (ii) neuraminidase inhibitors such as zanamivir and oseltamivir; (iii) peramivir and laninamivir octanoate, which might be effective against influenza virus following a single (intravenous or inhalation) administration; (iv) sofosbuvir, the (anticipated) cornerstone for the interferon-free therapy of HCV infections; (v) combinations of DAAs (direct antiviral agents) to achieve, in no time, a sustained virus response (SVR) against HCV infection; (vi) HIV protease inhibitors, the latest and most promising being darunavir; (vii) the integrase inhibitors (INIs) (raltegravir, elvitegravir, dolutegravir), representing a new dimension in the anti-HIV armamentarium; (viii), a new class of helicase primase inhibitors (HPIs) that may exceed acyclovir and the other anti-herpes compounds in both potency and safety; (ix) CMX-001, as the latest of Dr. Antonín Holý's legacy for its activity against poxviruses and CMV infections, and (x) noroviruses for which the ideal antiviral compounds are still awaited for. "
09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
04/01/2002 - "This includes, for the treatment of HIV infections, virus adsorption inhibitors (cosalane derivatives, cyanovirin-N), co-receptor antagonists (TAK-779, AMD3100), viral fusion inhibitors (pentafuside T-20, betulinic acid derivatives), viral uncoating inhibitors (azodicarbonamide), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs: emtricitabine, amdoxovir, dOTC, d4TMP prodrugs, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (NNRTIs: thiocarboxanilide UC-781, capravirine, SJ-3366, DPC 083, TMC 125/R165335), integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), protease inhibitors (atazanavir, mozenavir, tipranavir); for the treatment of RSV and paramyxovirus infections, viral fusion inhibitors (R170591, VP-14637, NMS03); for the treatment of picornavirus infections, viral uncoating inhibitors (pleconaril); for the treatment of pesti- (hepaci-, flavi-) virus infections, RNA replicase inhibitors (VP-32947); for the treatment of herpesvirus (HSV, VZV, CMV) infections, DNA polymerase inhibitors (A-5021, L- and D-cyclohexenylguanine); for the treatment of VZV infections, bicyclic furopyrimidine analogues; for the treatment of CMV infections, fomivirsen; for the treatment of DNA virus infections at large (papilloma-, polyoma-, herpes-, adeno- and poxvirus infections), cidofovir; for the treatment of influenza, neuraminidase inhibitors (zanamivir, oseltamivir, RWJ-270201); for the treatment of HBV infections, adefovir dipivoxil; for the treatment of HBV and HCV infections, N-glycosylation inhibitors (N-nonyl-deoxynojirimycin); and, finally, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors, for the treatment of various virus infections, including hemorrhagic fever virus infections."
|4.||T-Cell Leukemia (Leukemia, T Cell)
|5.||Acquired Immunodeficiency Syndrome (AIDS)
12/01/2006 - "This review reconstructs (in the general context of the history of AIDS research) the principal steps that led to the integrase inhibitors currently in clinical trials, and discusses possible future directions."
10/01/2014 - "Newly approved integrase inhibitors for clinical treatment of AIDS."
10/01/2010 - "Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: an overview."
09/01/2007 - "Development of integrase inhibitors for treatment of AIDS: an overview."
01/26/2006 - "However, there are currently no integrase inhibitors in clinical use for AIDS. "
|7.||Antiviral Agents (Antivirals)
|9.||DNA Primase (Primase)
|10.||HIV Protease Inhibitors
|3.||Highly Active Antiretroviral Therapy (HAART)
|4.||Drug Therapy (Chemotherapy)